$640 Million is the total value of Soleus Capital Management, L.P.'s 74 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 42.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $69,641,000 | +26.9% | 295,541 | -3.4% | 10.86% | +53.5% |
| Sell | ARCELLX INC | $16,448,000 | +18.5% | 909,739 | -8.1% | 2.57% | +43.4% | |
| KRYS | Sell | KRYSTAL BIOTECH INC | $14,083,000 | -26.8% | 214,482 | -25.9% | 2.20% | -11.6% |
| EPIX | Sell | ESSA PHARMA INC | $13,132,000 | -49.7% | 4,168,799 | -1.3% | 2.05% | -39.2% |
| ANGO | Sell | ANGIODYNAMICS INC | $12,965,000 | -41.4% | 670,000 | -34.7% | 2.02% | -29.1% |
| Sell | DICE THERAPEUTICS INC | $12,660,000 | -32.7% | 815,740 | -17.1% | 1.98% | -18.7% | |
| NRIX | Sell | NURIX THERAPEUTICS INC | $12,600,000 | -11.1% | 994,492 | -1.7% | 1.97% | +7.5% |
| EOLS | Sell | EVOLUS INC | $9,404,000 | -38.7% | 810,676 | -40.8% | 1.47% | -25.9% |
| ISEE | Sell | IVERIC BIO INC | $8,796,000 | -45.8% | 914,346 | -5.2% | 1.37% | -34.5% |
| STE | Sell | STERIS PLC | $7,691,000 | -22.9% | 37,310 | -9.6% | 1.20% | -6.8% |
| FATE | Sell | FATE THERAPEUTICS INC | $4,817,000 | -39.7% | 194,400 | -5.6% | 0.75% | -27.1% |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $4,727,000 | -67.2% | 100,000 | -50.6% | 0.74% | -60.4% |
| NTRA | Sell | NATERA INC | $4,674,000 | -25.9% | 131,873 | -14.9% | 0.73% | -10.3% |
| MIRM | Sell | MIRUM PHARMACEUTICALS INC | $3,815,000 | -49.6% | 196,018 | -42.9% | 0.60% | -39.0% |
| LNTH | Sell | LANTHEUS HLDGS INC | $3,646,000 | -63.1% | 55,222 | -69.1% | 0.57% | -55.3% |
| FGEN | Sell | FIBROGEN INC | $3,192,000 | -75.1% | 302,226 | -71.6% | 0.50% | -69.8% |
| Sell | IO BIOTECH INC | $3,061,000 | -14.1% | 655,404 | -2.6% | 0.48% | +3.9% | |
| XENE | Sell | XENON PHARMACEUTICALS INC | $2,282,000 | -60.7% | 75,000 | -60.5% | 0.36% | -52.5% |
| YMAB | Sell | Y-MABS THERAPEUTICS INC | $2,060,000 | -27.4% | 136,182 | -43.0% | 0.32% | -12.3% |
| Sell | XILIO THERAPEUTICS INC | $1,325,000 | -60.8% | 453,660 | -5.0% | 0.21% | -52.5% | |
| NVCR | Sell | NOVOCURE LTD | $923,000 | -35.5% | 13,275 | -23.2% | 0.14% | -22.2% |
| Sell | DA32 LIFE SCNCE TEC ACQSTN C | $485,000 | -50.1% | 50,000 | -50.0% | 0.08% | -39.2% | |
| OLK | Exit | OLINK HLDG ABsponsored ads | $0 | – | -53,961 | -100.0% | -0.12% | – |
| PCRX | Exit | PACIRA BIOSCIENCES INC | $0 | – | -22,250 | -100.0% | -0.22% | – |
| Exit | CYTEK BIOSCIENCES INC | $0 | – | -180,000 | -100.0% | -0.25% | – | |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -159,200 | -100.0% | -0.25% | – |
| LQDA | Exit | LIQUIDIA CORPORATION | $0 | – | -293,485 | -100.0% | -0.27% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -69,000 | -100.0% | -0.30% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -7,800 | -100.0% | -0.30% | – |
| ARYD | Exit | ARYA SCIENCES ACQU CORP IVcl a | $0 | – | -300,000 | -100.0% | -0.38% | – |
| SIEN | Exit | SIENTRA INC | $0 | – | -1,641,337 | -100.0% | -0.47% | – |
| NEO | Exit | NEOGENOMICS INC | $0 | – | -460,000 | -100.0% | -0.72% | – |
| TXG | Exit | 10X GENOMICS INC | $0 | – | -106,139 | -100.0% | -1.04% | – |
| SNN | Exit | SMITH & NEPHEW PLCspdn adr new | $0 | – | -385,000 | -100.0% | -1.58% | – |
| HOLX | Exit | HOLOGIC INC | $0 | – | -225,600 | -100.0% | -2.24% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INC | $0 | – | -3,055,193 | -100.0% | -2.67% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -62,300 | -100.0% | -2.81% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -1,408,100 | -100.0% | -16.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.